Murray Stahl's ALNY Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 2,272 shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $751,737, representing 0.01% of the portfolio. First purchased in 2020-Q2, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Murray Stahl has maintained a strategic position in ALNY, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 121 shares. Largest reduction occurred in Q3 2025, reducing 279 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -104 | Reduce 4.38% | 2,272 | $330.87 |
| Q4 2025 | -104 | Reduce 4.19% | 2,376 | $397.65 |
| Q3 2025 | -279 | Reduce 10.11% | 2,480 | $456.00 |
| Q2 2025 | -121 | Reduce 4.20% | 2,759 | $326.09 |
| Q4 2024 | +121 | Add 4.39% | 2,880 | $235.31 |
| Q3 2024 | -121 | Reduce 4.20% | 2,759 | $275.03 |
| Q4 2023 | -120 | Reduce 4.00% | 2,880 | $191.41 |
| Q2 2020 | +3,000 | New Buy | 3,000 | $148.00 |
Murray Stahl's Alnylam Pharmaceuticals Investment FAQs
Murray Stahl first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q2 2020, acquiring 3,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Alnylam Pharmaceuticals, Inc. (ALNY) for 24 quarters since Q2 2020.
Murray Stahl's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q2 2020, adding 3,000 shares worth $444,000.
According to the latest 13F filing for Q1 2026, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 2,272 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $751,737.
As of the Q1 2026 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.01% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 3,000 shares, as reported at the end of Q2 2020.